{"entity":{"id":"radiomer-therapeutics","kind":"company","name":"Radiomer Therapeutics","aka":[],"tldr":"Radiomer Therapeutics is a Houston start-up building radioactive cancer drugs that use a new kind of homing molecule, part DNA and part protein, to find tumour cells. It planned small imaging studies in patients first, before moving to treatment.","summary":"Radiomer Therapeutics was launched in May 2024 by Fannin Partners, the Houston life-science company builder, with undisclosed pre-seed funding. It uses Fannin's Raptamer platform, peptide-oligonucleotide hybrids built on a single-stranded DNA backbone decorated with peptide-like side chains, as targeting ligands for theranostic radiopharmaceuticals. The launch release named breast, lung, colorectal, prostate and head and neck cancers as areas of interest and said lead programmes were expected to complete phase 0 imaging and dosimetry trials in cancer patients in the first quarter of 2025, followed by therapeutic programmes. Atul Varadhachary, Fannin's managing partner, is CEO.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.radiomer.com/"},{"label":"Launch press release (PRWeb)","url":"https://www.prweb.com/releases/fannin-launches-radiomer-therapeutics-with-novel-targeting-vectorligand-platform-for-radiopharmaceuticals-302156353.html"},{"label":"InnovationMap Houston: Fannin launches Radiomer","url":"https://houston.innovationmap.com/houston-fannin-partners-radiomer-therapeutics-2668405362.html"}],"tags":[],"related":[],"cancers":["breast-cancer","lung-cancer","colorectal","prostate","head-and-neck"],"sections":["radiopharma"],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year 2023 and the launch date are from Fannin's launch release (PRWeb, 29 May 2024). Whether the planned phase 0 studies were completed was not confirmed: the company website gives no pipeline detail and its sub-pages returned 404."],"hq":"Houston, TX","country":"US","companyType":"radiopharma","website":"https://www.radiomer.com/","founded":2023,"stage":"startup","investors":[],"funding":[]},"route":"/companies/radiomer-therapeutics/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}]}}